Der CJ - Search Results

1

Genome-wide DNA methylation analysis of KRAS mutant cell lines.

Tew BY, Durand JK, Bryant KL, Hayes TK, Peng S, Tran NL, Gooden GC, Buckley DN, Der CJ, Baldwin AS, Salhia B. Tew BY, et al. Among authors: der cj. Sci Rep. 2020 Jun 23;10(1):10149. doi: 10.1038/s41598-020-66797-x. Sci Rep. 2020. PMID: 32576853 Free PMC article.

2

Aberrant function of the Ras signal transduction pathway in human breast cancer.

Clark GJ, Der CJ. Clark GJ, et al. Among authors: der cj. Breast Cancer Res Treat. 1995 Jul;35(1):133-44. doi: 10.1007/BF00694753. Breast Cancer Res Treat. 1995. PMID: 7612899 Review.

3

Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, Baldwin AS Jr. Finco TS, et al. Among authors: der cj. J Biol Chem. 1997 Sep 26;272(39):24113-6. doi: 10.1074/jbc.272.39.24113. J Biol Chem. 1997. PMID: 9305854 Free article.

4

Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras.

Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, Lowe SW, Der CJ, Baldwin AS Jr. Mayo MW, et al. Among authors: der cj. Science. 1997 Dec 5;278(5344):1812-5. doi: 10.1126/science.278.5344.1812. Science. 1997. PMID: 9388187

5

Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.

Hao H, Muniz-Medina VM, Mehta H, Thomas NE, Khazak V, Der CJ, Shields JM. Hao H, et al. Among authors: der cj. Mol Cancer Ther. 2007 Aug;6(8):2220-9. doi: 10.1158/1535-7163.MCT-06-0728. Mol Cancer Ther. 2007. PMID: 17699719

6

Ras-driven transformation of human nestin-positive pancreatic epithelial cells.

Campbell PM, Lee KM, Ouellette MM, Kim HJ, Groehler AL, Khazak V, Der CJ. Campbell PM, et al. Among authors: der cj. Methods Enzymol. 2008;439:451-65. doi: 10.1016/S0076-6879(07)00431-4. Methods Enzymol. 2008. PMID: 18374182

7

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Yeh JJ, Routh ED, Rubinas T, Peacock J, Martin TD, Shen XJ, Sandler RS, Kim HJ, Keku TO, Der CJ. Yeh JJ, et al. Among authors: der cj. Mol Cancer Ther. 2009 Apr;8(4):834-43. doi: 10.1158/1535-7163.MCT-08-0972. Mol Cancer Ther. 2009. PMID: 19372556 Free PMC article.

8

Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?

Roberts PJ, Stinchcombe TE, Der CJ, Socinski MA. Roberts PJ, et al. Among authors: der cj. J Clin Oncol. 2010 Nov 1;28(31):4769-77. doi: 10.1200/JCO.2009.27.4365. Epub 2010 Oct 4. J Clin Oncol. 2010. PMID: 20921461 Review.

9

Are all KRAS mutations created equal?

Stinchcombe TE, Der CJ. Stinchcombe TE, et al. Among authors: der cj. Lancet Oncol. 2011 Aug;12(8):717-8. doi: 10.1016/S1470-2045(11)70200-5. Epub 2011 Jul 22. Lancet Oncol. 2011. PMID: 21782508 No abstract available.

10

The RalB small GTPase mediates formation of invadopodia through a GTPase-activating protein-independent function of the RalBP1/RLIP76 effector.

Neel NF, Rossman KL, Martin TD, Hayes TK, Yeh JJ, Der CJ. Neel NF, et al. Among authors: der cj. Mol Cell Biol. 2012 Apr;32(8):1374-86. doi: 10.1128/MCB.06291-11. Epub 2012 Feb 13. Mol Cell Biol. 2012. PMID: 22331470 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

387 results

Search Page